GlassScriptPhysician profile
Matthew William Pott
NPI 1952117590
$1,081.39
in general payments reported to CMS, 2019-2025
14 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $212.35 | 2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $208.08 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.12 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $120.89 | 2025 | Airsupra |
| Exact Sciences Corporation | $84.51 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $75.80 | 2025 | Mounjaro, Zepbound, Kisunla |
| Lundbeck LLC | $74.14 | 2025 | Vyepti |
| Pfizer INC. | $43.83 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.15 | 2025 | |
| Novo Nordisk INC | $20.34 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.62 | 2025 | Xhance, Nuzyra |
| Phadia US INC. | $18.80 | 2025 | Immunocap |
| Bioventus LLC | $17.03 | 2025 | |
| Aimmune Therapeutics, INC. | $15.73 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.